MedTrace Logo

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

NCT03470311 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-01-20

No results posted yet for this study

Summary

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control

Conditions

  • Severe Prednisone Dependent Eosinophilic Asthma

Interventions

BIOLOGICAL

Benralizumab

30mg in 1mL pre-filled syringe

BIOLOGICAL

Placebo

Matched placebo (1mL) in pre-filled syringe

Sponsors & Collaborators

Principal Investigators

  • Parameswaran Nair, MD, PhD · McMaster University and St. Joseph's Healthcare Hamilton

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-26
Primary Completion
2022-06-14
Completion
2022-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03470311 on ClinicalTrials.gov